This is a working overview of mass confirmation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-11 and is reviewed periodically as new material appears.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (dry) | -20 °C | Protected from light and moisture |
| Storage temperature (solution) | -80 °C | Single-use aliquots recommended |
| Identity assay | LC-MS or MALDI-TOF | Confirms mass near 889 Da |
| Purity assay | RP-HPLC | Reports main peak percentage |
| Common impurities | Truncated peptides, deamidated forms | Arise from synthesis or storage |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
For laboratory quantities, up to 40 are possible. To prepare larger peptides, individual fragments are first produced and purified, and then combined to the final molecule by liquid phase synthesis. Thus, for the production of Roche's anti-AIDS drug Fuzeon (enfuvirtide), three fragments of 10–12 amino acids are first made by solid-phase synthesis and then linked together by liquid-phase synthesis. The preparation of the whole 35 amino acid peptide requires more than 130 individual steps. Microreactor Technology (MRT), used for process intensification, is a relatively new tool that is being developed at several universities, as well as fine chemical companies, such as Bayer Technology Services, Germany; Clariant, Switzerland; Evonik-Degussa, Germany; DSM, The Netherlands; Lonza, Switzerland; PCAS, France; and Sigma-Aldrich, US. The lattermost company produces about 50 fine chemicals up to multi-kilogram quantities in microreactors. From a technological point of view, MRT, or continuous flow reactors, represents the first breakthrough development in reactor design since the introduction of the stirred-tank reactor, which was used by Perkin & Sons when they established a factory on the banks of what was then the Grand Junction Canal in London in 1857, in order to produce mauveïne, the first-ever synthetic purple dye. For a comprehensive coverage of the subject see Micro Process Engineering. Reactions that have worked in microreactors include aromatics oxidations, diazomethane conversions, Grignards, halogenations, hydrogenations, nitrations, and Suzuki couplings.
Primary myelofibrosis (PMF) is a rare bone marrow blood cancer. It is classified by the World Health Organization (WHO) as a type of myeloproliferative neoplasm, a group of cancers in which there is activation and growth of mutated cells in the bone marrow. This is most often associated with a somatic mutation in the JAK2, CALR, or MPL genes. In PMF, the bony aspects of bone marrow are remodeled in a process called osteosclerosis; in addition, fibroblasts secrete collagen and reticulin proteins that are collectively referred to as fibrosis. These two pathological processes compromise the normal function of bone marrow, resulting in decreased production of blood cells such as erythrocytes (red cells), granulocytes, and megakaryocytes. The latter are responsible for the production of platelets. Signs and symptoms include fever, night sweats, bone pain, fatigue, and abdominal pain. Increased infections, bleeding and an enlarged spleen (splenomegaly) are also hallmarks of the disease. Patients with myelofibrosis have an increased risk of acute meyloid leukemia and frank bone marrow failure. In 2016, prefibrotic primary myelofibrosis was formally classified as a distinct condition that progresses to overt PMF in many patients, the primary diagnostic difference being the grade of fibrosis.
CoviVac – COVID vaccine Cytestrol acetate – antiestrogen, cytostatic antineoplastic agent Deltaran (delta sleep-inducing peptide) – alcohol withdrawal treatment Dilept (GZR-123) – antipsychotic, neurotensin analogue Diucifon – leprostatic agent Emoxypine (Mexidol; Mexifin) – actoprotector, antioxidant EpiVacCorona – COVID vaccine Eprobemide (Befol) – antidepressant, reversible inhibitor of monoamine oxidase A Ethacizine (ethacyzine; Ethacizin) – antiarrhythmic agent Fabomotizole (Afobazole) – anxiolytic Feprosidnine (Sydnophen) – amphetamine derivative, psychostimulant Fluacizine (Phtorazisin) – tricyclic antidepressant, phenothiazine Fluorothiazinone (CL-55; Ftortiazinon) – investigational antibiotic Fotretamine (Fotrin) – alkylating antineoplastic agent, immunosuppressant Gamofen (gamophen; amphetamine–GABA) – amphetamine derivative, GABATooltip γ-aminobutyric acid analogue, central agent, central depressant Gidazepam (hydazepam, hidazepam) – atypical benzodiazepine, anxiolytic, TSPOTooltip translocator protein agonist/ligand Gludantan (gludantane) – adamantane, antiparkinsonian agent, antidepressant Glufimet (RGPU-238; dimethyl 3-phenylglutamate) – GABATooltip γ-aminobutyric acid and phenibut analogue Glutaron (RGPU-135; neuroglutamine, neuroglutam; β-phenylglutamate; 3-phenylglutamate) – glutamate analogue, psychostimulant, antidepressant, anxiolytic, neuroprotective Hemantane (hymantane) – adamantane, antiparkinsonian agent Hopantenic acid (homopantothenic acid; N-pantoyl-GABA; Pantogam) – central depressant, GABATooltip γ-aminobutyric acid analogue Ipidacrine (Neiromidin) – acetylcholinesterase inhibitor Latrepirdine (dimebolin; Dimebon) – antihistamine, antiserotonergic, nootropic Mecigestone (pentarane B) – progestin Megestrol caproate (MGC) – progestin Meldonium (Mildronate) – anti-ischemia agent Menthyl isovalerate (validolum; Extravalerianic, Validol, Valofin, Menthoval) – anxiolytic Mesocarb (Sidnocarb, Sydnocarb, Synocarb) – amphetamine derivative, psychostimulant Methylphenatine – amphetamine derivative, psychostimulant Methylphenylpiracetam – racetam, sigma σ1 receptor positive allosteric modulator α-Methyltryptamine (αMT; Indopan) – tryptamine derivative, antidepressant Metralindole (Inkazan) – antidepressant, reversible inhibitor of monoamine oxidase A Moracizine (moricizine; Ethmozine) – antiarrhythmic agent Nooglutyl (Nooglutil; N-5-hydroxynicotinoyl-L-glutamate) – nootropic Orenetide (BP101; Libicore; Desirix; Thr-Lys-Pro-Arg-Pro) – investigational small peptide, sexual enhancer Pabofen (pabophen; amphetamine–PABA) – amphetamine derivative, antihypoxic agent Pentarane A (D'6-pentarane) – progestin Phemerazole (femerazol; 5-phenyl-3-methylpyrazole) – sedative, hypnotic, anticonvulsant, muscle relaxant, mammary stimulant Phenatine (phenatin; Fenatine; amphetamine–niacin; N-nicotinoylamphetamine) – amphetamine derivative, psychostimulant, hypotensive agent Phenazepam – benzodiazepine, anxiolytic, sedative, hypnotic Phenibut (β-phenyl-GABA; Anvifen, Fenibut, Noofen; Citrocard, RGPU-147) – central depressant, anxiolytic, GABATooltip γ-aminobutyric acid analogue, gabapentinoid N-Phenylacetyl-L-prolylglycine ethyl ester (omberacetam; Noopept) – nootropic, racetam, cyclic glycine-proline prodrug Phenylphenamine (phenylamphetamine) – amphetamine derivative Phenylpiracetam (fonturacetam; Phenotropil, Actitropil, Carphedon) – psychostimulant, nootropic, racetam Phenylpiracetam hydrazide (fonturacetam hydrazide) – anticonvulsant, racetam Picamilon (N-nicotinoyl-GABA, pycamilon, and pikamilon) – anxiolytic, GABATooltip γ-aminobutyric acid analogue Pipofezine (Azafen, Azaphen) – tricyclic antidepressant Pirlindole (Lifril, Pyrazidol) – antidepressant, reversible inhibitor of monoamine oxidase A, serotonin–norepinephrine reuptake inhibitor Polymethylsiloxane polyhydrate (PMSPH; methylsilicic acid hydrogel; Enterosgel) – enterosorbent Propylphenamine (propylamphetamine; possibly N-propylamphetamine) – amphetamine derivative Prospidium chloride (prospidine) – cytostatic, anti-inflammatory agent Pyridoxiphen (amphetamine–pyridoxine; pyridoxylamphetamine) – amphetamine derivative, sympatholytic, hypotensive agent Quifenadine (Phencarol, Fencarol) – antihistamine RGPU-95 (p-chlorophenylpiracetam) – antidepressant, anxiolytic, racetam RGPU-207 (cyclic GABA derivative) – GABATooltip γ-aminobutyric acid analogue, mitochondrial modulator, racetam RGPU-260 – GABATooltip γ-aminobutyric acid analogue, cardiac stimulant Riamilovir (Triazavirin) – antiviral RU-1205 – analgesic, kappa opioid receptor agonist Selank – tuftsin analogue, nootropic, anxiolytic Semax – ACTHTooltip adrenocorticotropic hormone fragment analogue, nootropic, neuroprotective, neurorestorative Sodium polydihydroxyphenylene thiosulfonate (Hypoxen) – antihypoxic agent Sputnik Light – COVID vaccine Sputnik V – COVID vaccine Sulfozinum (sulfazin) – pyrogenic and pain-inducing agent used in psychiatry, for instance psychosis Temgicoluril (tetramethylglycoluril; Adaptol, Mebicar, Mebicarum, Mebikar) – anxiolytic Testifenon (testiphenon, testiphenone, chlorphenacyl dihydrotestosterone ester) – androgen/anabolic steroid, cytostatic antineoplastic agent Tetrindole – antidepressant, reversible inhibitor of monoamine oxidase A Thiophenatine (N-thionicotinoylamphetamine) – amphetamine derivative Tipindole – serotonin antagonist and monoamine oxidase inhibitor Tolibut (β-(4-methylphenyl)-GABA)) – anxiolytic, analgesic, neuroprotective, GABATooltip γ-aminobutyric acid and phenibut analogue Traneurocin (cycloprolylglycine; CPG; NA-831) – racetam-like neuroprotective, neurogenic, nootropic, and anxiolytic Trimeperidine – opioid analgesic Umifenovir (Arbidol) – antiviral Vishnevsky liniment – topical wound medication Phenamine (Fenamin), a psychostimulant, is not specifically a Russian drug but is rather the Russian name for amphetamine.
=== Synthetic analogues === Many vitamin B1 analogues, such as Benfotiamine, fursultiamine, and sulbutiamine, are synthetic derivatives of thiamine. Most were developed in Japan in the 1950s and 1960s as forms that were intended to improve absorption compared to thiamine. Some are approved for use in some countries as a drug or non-prescription dietary supplement for treatment of diabetic neuropathy or other health conditions.
Argentine diplomacy considered the interference of the Peruvians in the war against Paraguay, as well as in the internal affairs of the Argentine state, as something of less relevance compared to the interference of the Chileans, despite the fact that Peru and Chile collaborated (until end of 1867) against the objectives of the Triple Alliance, which would demonstrate discriminatory conduct of Argentine diplomacy against the Peruvians, portrayed as servile puppets and marionette of the Chileans. Meanwhile, Argentine diplomats came to accuse Chile of meddling in Bolivian politics, manipulating them to carry out anti-Argentine policies; and support the Revolution of the Colorados, carried out by federal opponents of the government of President Mitre. The dissident press of Argentina and Uruguay (opposed to their governments and in solidarity with Chile and Peru), which questioned the foreign policy carried out by their foreign ministries, was attacked by their respective governments, being restricted and even prohibited from circulating in Argentina. Meanwhile, the newspapers of the Spanish immigrant communities, extolling the action of the Spanish Navy in the South Pacific against the Peruvian and Chilean navies (during the Spanish-South American War), circulated freely in the cities. Argentine, which evidenced anti-Peruvian and anti-Chilean biases. Another example of these biases occurs when analyzing and comparing the newspapers El Mercurio of Valparaíso and La Nación Argentina of Buenos Aires.
Sources: en.wikipedia.org
=== Karyotyping === The routine chromosome analysis (Karyotyping) refers to analysis of metaphase chromosomes which have been banded using trypsin followed by Giemsa, Leishmanns, or a mixture of the two. This creates unique banding patterns on the chromosomes. The molecular mechanism and reason for these patterns are unknown, although it's likely related to replication timing and chromatin packing. Several chromosome-banding techniques are used in cytogenetics laboratories. Quinacrine banding (Q-banding) was the first staining method used to produce specific banding patterns. This method requires a fluorescence microscope and is no longer as widely used as Giemsa banding (G-banding). Reverse banding, or R-banding, requires heat treatment and reverses the usual black-and-white pattern that is seen in G-bands and Q-bands. This method is particularly helpful for staining the distal ends of chromosomes. Other staining techniques include C-banding and nucleolar organizing region stains (NOR stains). These latter methods specifically stain certain portions of the chromosome. C-banding stains the constitutive heterochromatin, which usually lies near the centromere, and NOR staining highlights the satellites and stalks of acrocentric chromosomes. High-resolution banding involves the staining of chromosomes during prophase or early metaphase (prometaphase), before they reach maximal condensation.
== A scientific home in Pittsburgh == In a few short years, the Dean of the School of Medicine, himself a professor of Biochemistry, invited Hofmann to become Chairman of the Department. From the moment he took the position of Chairman of Biochemistry, it became clear that although he would always be a son of Switzerland, the United States offered him career opportunities he could never hope for in a small country like Switzerland. The US was to become his permanent home. The burgeoning field of peptide chemistry became his scientific focus and, in his own words, he fell in love with a molecule that was known to stimulate the adrenal cortex to produce the very steroids that had so fascinated him in Reichstein's laboratory. That molecule, not yet isolated, was ACTH and the love affair was lifelong. Despite detours into other areas, he kept returning to ACTH. In the last years before his death, he was developing methods to isolate the ACTH receptor.
== Composition == The characteristic substances inside the extracellular matrix of soft tissue are the collagen, elastin and ground substance. Normally the soft tissue is very hydrated because of the ground substance. The fibroblasts are the most common cell responsible for the production of soft tissues' fibers and ground substance. Variations of fibroblasts, like chondroblasts, may also produce these substances.
Clathurellinae was split into three families: Borsoniidae (also including species from Turridae), Mitromorphidae and Clathurellidae (all previously lumped under the Turridae). Conorbiinae was raised to the rank of family Conorbidae, consisting of three genera: Artemidiconus da Motta, 1991, Benthofascis Iredale, 1936, and Conorbis Swainson, 1840. Mangeliinae and Oenopotinae were combined and raised to the rank of family Mangeliidae, which had previously been lumped in the Turridae). Raphitominae was raised to the rank of family Raphitomidae (also previously lumped in the Turridae). The classification by Bouchet et al. (2011) was based on mitochondrial DNA and nuclear DNA testing, and built on the prior work by J.K. Tucker & M.J. Tenorio (2009), but did not include fossil taxa. Molecular phylogeny, particularly with the advent of nuclear DNA testing in addition to the mDNA testing (testing in the Conidae initially began by Christopher Meyer and Alan Kohn), is continuing on the Conidae.
The vaccine is free of charge to users in Russia and Kazakhstan. The cost per dose would be less than US$10 (US$20 for the required two doses) on international markets, much less than the cost of mRNA vaccines from other manufacturers. Kirill Dmitriev, head of the fund, told reporters that over 1 billion doses of the vaccine are expected to be produced in 2021 outside of Russia. The head of the Gamaleya Research Institute Alexander Ginzburg estimated that it would take 9–12 months to vaccinate the vast majority of the Russian population, assuming in-country resources were adequate. The commercial release of the Gam-COVID-Vac was first scheduled for September 2020. In October, Mikhail Murashko said that the Gam-COVID-Vac would be free for all Russian citizens after the launching of mass production. Later on, the Russian Ministry of Health registered the maximum ex-factory price equal to 1,942 rubles for two components and included it into The National List of Essential medicines. There were also suggestions to include the vaccine in the National Immunisation Calendar of Russia. In the beginning of December 2020, Russian authorities announced the start of a large-scale free of charge vaccination with Gam-COVID-Vac for Russian citizens: the immunization program was launched on 5 December 2020 (with 70 medical centres in Moscow providing vaccinations). Doctors and other medical workers, teachers, and social workers were given priority due to their highest risk of exposure to the disease.
Sources: en.wikipedia.org
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.
Reverse-phase HPLC assesses purity, and mass spectrometry confirms molecular mass. The combination helps distinguish the target peptide from truncated or modified impurities.
Buffer composition, pH, adsorption to containers, and freeze-thaw history can all affect the amount of intact peptide in solution. These factors may change results even when the starting material is chemically correct.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.